Molecular and Cellular Probes

Papers
(The H4-Index of Molecular and Cellular Probes is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma39
LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression35
Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance31
The tricks for fighting against cancer using CAR NK cells: A review29
A SYBR Green I-based real-time polymerase chain reaction assay for detection and quantification of canine bufavirus28
Development of a cell-based reporter assay for detection of Human alphaherpesviruses25
THBS1 knockdown suppresses pancreatic cancer progression through JAK2/STAT3 signaling pathway24
MiR-125b-1-3p-mediated UQCRB inhibition facilitates mitochondrial metabolism disorders in a rat cellular senescencemodel21
Down-regulated circ_0001853 inhibits lipopolysaccharide-induced endometritis progression via sponging miR-34c-5p21
Metagenomic next-generation sequencing for detection of pathogens in children with hematological diseases complicated with infection19
Clinical significance analysis of microRNA-199a-3p in gingival crevicular fluid for patients with chronic periodontitis18
The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer18
Histone H3 K27 alterations in central nervous system tumours: Challenges and alternative diagnostic approaches17
A real-time recombinase polymerase amplification assay for fast and accurate detection of Ditylenchus destructor14
The measurement of NRF2 and TP53 in blood expects radiotherapeutic sensitivity in patients with esophageal cancer14
0.13018107414246